ARTICLE | Clinical News
Pirfenidone regulatory update
March 26, 2007 7:00 AM UTC
Shionogi submitted a marketing application in Japan for pirfenidone to treat idiopathic pulmonary fibrosis (IPF). Shionogi has Japanese rights to the oral p38 mitogen-activated protein (MAP) kinase in...